296 related articles for article (PubMed ID: 26976998)
1. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Mian M; Tinelli M; DE March E; Turri G; Meneghini V; Pescosta N; Berno T; Marabese A; Mondello P; Patriarca F; Pizzolo G; Semenzato G; Cortelazzo S; Zambello R
Anticancer Res; 2016 Mar; 36(3):1059-65. PubMed ID: 26976998
[TBL] [Abstract][Full Text] [Related]
2. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
5. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
6. [First-line treatment of multiple myeloma].
Breitkreutz I; Raab M; Goldschmidt H
Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
8. Stem Cell Transplantation in Multiple Myeloma.
Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
[TBL] [Abstract][Full Text] [Related]
10. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
11. New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H; McCarthy P
Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Koeppen S
Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
14. Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
Rajan AM; Rajkumar SV
Semin Oncol; 2016 Dec; 43(6):700-702. PubMed ID: 28061990
[TBL] [Abstract][Full Text] [Related]
15. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Tazawa S; Shiozawa E; Homma M; Arai N; Kabasawa N; Kawaguchi Y; Fujiwara S; Okino K; Kobayashi K; Yamochi T; Tate G; Nakamaki T; Takimoto M
J Clin Exp Hematop; 2015; 55(3):121-6. PubMed ID: 26763359
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Sengsayadeth S; Malard F; Savani BN; Garderet L; Mohty M
Blood Cancer J; 2017 Mar; 7(3):e545. PubMed ID: 28338672
[TBL] [Abstract][Full Text] [Related]
17. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang L; Ran X; Wang B; Sheng Z; Liu L
Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367
[TBL] [Abstract][Full Text] [Related]
18. [Use of new drugs within primary therapy of multiple myeloma].
Štork M; Krejčí M; Sandecká V; Král Z; Pour L
Vnitr Lek; 2016; 62(5):413-22. PubMed ID: 27319235
[TBL] [Abstract][Full Text] [Related]
19. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
[TBL] [Abstract][Full Text] [Related]
20. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]